Kramkimel N., Thomas-Schoemann A., Sakji L., Golmard J., Noe G., Regnier-Rosencher E., Chapuis N., Maubec E., Vidal M., Avril M., Goldwasser F., Mortier L., Dupin N., Blanchet B.   Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.  Target. Oncol..  2016 ;11 :59-69

Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib were prospectively analyzed. Vemurafenib plasma concentration (n = 159) was measured at days 15, 30, 60, and 90 after treatment initiation. Clinical and biological determinants (including plasma vemurafenib concentration) for efficacy and safety were assessed using Cox's model and multivariate stepwise logistic regression. Median progression-free survival (PFS) and overall survival were 5.0 (95 % confidence interval [95 % CI] 2.0-6.0) and 11.0 (95% CI 7.0-16.0) months, respectively. Twenty-nine patients (49 %) experienced any grade >/=3 toxicity and the most frequent grade >/=2 toxicity was skin rash (37 %). Severe toxicities led to definitive discontinuation in seven patients (12 %). Grade >/=2 skin rash was not statistically associated with better objective response at day 60 (p = 0.06) and longer PFS (hazard ratio 0.47; 95 % CI 0.21-1.08; p = 0.075). Grade >/=2 skin rash was statistically increased in patients with ECOG >/= 1 (odds ratio 4.67; 95 % CI 1.39-15.70; p = 0.012). Vemurafenib concentration below 40.4 mg/L at day 15 was significantly associated with a shorter PFS (1.5 [0.5-5.5] vs. 4.5 [2-undetermined] months, p = 0.029). Finally, vemurafenib concentration was significantly greater in patients developing grade >/=2 rash (61.7 +/- 25.0 vs. 36.3 +/- 17.9 mg/L, p < 0.0001). These results suggest that early plasma drug monitoring may help identify outpatients at high risk of non-response or grade >/= 2 skin rash.

Kerbage Y., Azaïs H., Estevez J. P., Merlot B., Collinet P.   Current controversies regarding power morcellation and future directions.  Gynecol. Obstet. Fertil..  2016 ;44 :417-423

Modern surgery tends to the improvement of minimally invasive strategies. Laparoscopy, rooted in practices for years, supplanted laparotomy in many directions. Regarding the extraction of large uterus, morcellation is currently the only way to externalize surgical specimens (myomas, uterine), without increasing the skin opening while allowing to reduce postoperative complications compared to laparotomy. However, in 2014, the Food and Drug Administration (FDA) discourages the use of uterine morcellation because of oncological risk. This recommendation has been challenged by a part of the profession. Our review has sought to identify the evidence for and against the use of morcellation. We also tried to quantify surgical risk and the current means of prevention. The incidence of uterine sarcomas is still poorly identified and preoperative diagnostic facilities remain inadequate. The small number of retrospective studies currently available could not enable any recommendation. The evaluation of morcellation devices and the improvement of preoperative diagnosis modalities (imaging, preoperative biopsy) are to continue to minimize the oncological risk.

Kantola E., Rantamaki A., Leino I., Penttinen J. P., Mordon S., Guina M.   5 W YELLOW-ORANGE COMPACT SEMICONDUCTOR LASER FOR THE TREATMENT OF VASCULAR LESIONS.  Lasers Surg. Med..  2016 ;48 :11-11
Jaillard A., Baillet C., Béron A., Tabibzadeh N., Scherpereel A., Frimat M., Perbet R., Gnemmi V., Noël C., Huglo D.   FDG PET/CT allowing detection and follow-up of tumor cell transplantation.  Ann. Nucl. Med..  2016 ;30 :250-254

After detection of small cell lung cancer in a 67-year-old patient who had donated a kidney 7 months earlier, the graft recipient underwent FDG-PET/CT to determine the presence/absence of tumor cell transmission. It showed abnormal increased uptake of the renal graft, associated with hypermetabolic lymph nodes and hepatic, pulmonary and bone lesions. Emergency graft resection was performed 5 days after PET/CT, permitting immunosuppressive therapy withdrawal. Pathologic examination of the kidney showed parenchymal infiltration by tumor cells compatible with small cell lung cancer. Thereafter, pathologists proved that the recipient's and donor's tumor cells matched using microsatellite markers. FDG-PET/CT was performed in the follow-up and showed progression in the donor despite chemotherapy and radiotherapy. He died a few months later. However, FDG-PET/CT showed a complete metabolic response after only 3 courses of chemotherapy in the recipient.

Jacobsoone-Ulrich A., Jamme P., Alkeraye S., Dzwiniel V., Faure E., Templier C., Mortier L.   Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.  Melanoma Res..  2016 ;26 :153-156

Targeted therapy and immunotherapy in metastatic melanoma have led to a marked improvement in patients' survival and their quality of life. Although there are data on anti-programmed-death-receptor-1 (anti-PD1) after ipilimumab, only few data are available on ipilimumab following anti-PD1 as the first-line treatment. The aim of our study was to evaluate tolerance and survival of patients treated with ipilimumab as the second-line immunotherapy among metastatic melanoma patients following anti-PD1 treatment. Retrospective and descriptive epidemiological studies were carried out at the Dermatology Department of the University Hospital of Lille. We describe a case series of patients treated with ipilimumab after anti-PD1 failure for metastatic melanomas. For each patient, we assessed disease extension since ipilimumab introduction using RECIST 1.1. The time between ipilimumab introduction and other systemic treatment and overall survival (between ipilimumab introduction and last patient visit) was assessed. The effect of ipilimumab after anti-PD1 treatment was evaluated in eight patients. Four patients responded to ipilimumab: three showed a complete response and one showed a partial response. For these patients, the time period between the first ipilimumab injection and another systemic treatment ranged from 209 to 391 days and the overall survival ranged from 314 to 581 days. One patient showed grade 3 chorioretinitis, an unusual toxicity with ipilimumab or anti-PD1 to our knowledge. We have described the efficacy of ipilimumab following anti-PD1 in metastatic melanoma in eight patients. Several comparative studies are still in progress, and their results will be important to develop an optimal therapeutic strategy for our patients.

Heidenreich A., Shore N., Villers A., Klotz L., Siemens D. R., van Os S., Baron B., Wang F., Chowdhury S.   Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN.  Ann. Oncol..  2016 ;27
Hansson J., Hauschild A., Kunstfeld R., Grob J. J., Dreno B., Mortier L., Ascierto P. A., Licitra L. F., Dutriaux C., Thomas L., Meyer N., Guillot B., Dummer R., Arenberger P., Fife K., Raimundo A., Dika E., Dimier N., Xynos I., Basset-Seguin N.   Visnnodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).  J. Clin. Oncol..  2016 ;34 :9532-9532
Grob J. J., Bartley K., Kuntsfeld R., Dreno B., Mortier L., Ascierto P. A., Dutriaux C., Meyer N., Guillot B., Dummer R., Williams S., Fittipaldo A., Ernst D. S., Hauschild A., Basset-Seguin N., Hansson J.   Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study.  J. Am. Acad. Dermatol..  2016 ;74 :AB193-AB193
Garabedian C., Rubod C., Faye N., Ledu N. K., Merlot B., Collinet P.   Improved surgical management through optimized imaging of pelvic endometriosis.  Minerva Ginecol.  2016 ;68 :713-21
Durand M., Jain M., Robinson B., Aronowitz E., El Douahy Y., Leung R., Scherr D. S., Ng A., Donzeau D., Amiel J., Spincemaille P., Villers A., Ballon D.   HIGH-RESOLUTION MAGNETIC RESONANCE IMAGING DIFFERENTIATES BETWEEN NORMAL HISTOMORPHOLOGICAL SIGNATURES AND PROSTATE CANCER IN THE RESECTED PROSTATE GLAND.  J. Urol..  2016 ;195 :E159-E160